The liver fibrosis market is entering a transformative phase, driven by greater awareness, improved diagnostic ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Gone are the days of battling obesity with a limited toolbox. With more weight loss supplements and drugs on the market than ever before, deciding which medication is right for you isn' ...

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...

Blue Cross Blue Shield of Michigan is engaged in the most consequential reimbursement negotiations with hospitals in its ...

The Shapiro administration's plan would limit Ozempic access under Medicaid to save costs. Not everyone is on board.

Denmark-based multinational pharmaceutical company Novo Nordisk will be making available in the Philippines within this year Wegovy, its approved weight loss treatment for ...

Hims & Hers has been expanding its presence in the weight management market, with its existing Novo partnership representing ...

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...

GoodRx says that with the support of a healthcare team, a clear transition plan, and a few cost-saving tools, you can make ...

The European Medicines Agency’s safety committee said on Friday Novo Nordisk’s popular weight-loss and diabetes drugs Wegovy ...